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Abstract
Background: The purpose of this study was to assess platelet morpho-
logical parameters in children and adolescents with type 1 diabetes mel-
litus (T1DM) and to determine the factors affecting those parameters.
Methods: A total of 80 children with type 1 diabetes mellitus and 80 
healthy control subjects were included in this study. All subjects’ plate-
let parameters including platelet count (PLT), mean platelet volume 
(MPV), platelet distribution width (PDW) and plateletcrit (PCT) lev-
els were measured. Age at diagnosis, duration of diabetes, and hemo-
globin A1c (HbA1c) levels of patients with T1DM were also recorded.
Results: There was no significant difference in PLT, MPV, PDW and 
PCT values between patients and controls (P > 0.05). PCT and PLT 
values were higher in patients with poor metabolic control compared 
to the other cases (P = 0.002, P = 0.005). Positive correlation was 
found between HbA1c and PCT (r = 0.28, P = 0.01). There was no 
correlation between HbA1c and MPV, PDW and PLT.
Conclusions: Indices of platelet morphology such as PCT, PLT, PDW 
and MPV were similar in children with T1DM and in healthy con-
trols. However, an increase in PCT values in poor glycemic control 
group and a significant positive correlation between PCT and HbA1c 
were observed, suggesting that PCT levels may be an early marker of 
vascular complication.
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Introduction
Type 1 diabetes mellitus (T1DM) is one of the most com-
mon endocrinological disorders in children and adolescents. 
Its incidence below the age of 14 ranges from 0.1/100,000 to 
36.8/100,000 annually, and varies between countries [1]. Micro-
vascular (retinopathy, neuropathy, and nephropathy) and macro-
vascular (coronary artery disease, peripheral artery disease, and 
cerebrovascular disease) atherothrombotic complications may 
develop in children and adolescents, depending on duration of 
diabetes, degree of metabolic control, and other factors (such 
as genetic and smoking). Hyperglycemia, dyslipidemia, inflam-
mation and stress are factors that increase the risk of vascular 
complications in patients with T1DM. The majority of ischemic 
events are known to develop due to intravascular thrombosis. 
Platelet activation plays a key role in the development of athero-
sclerosis. Type 1 and type 2 diabetes have platelet hyperactivity, 
dysfunction and changed morphology which lead to thrombus 
formation, microvascular embolization and discharge of oxida-
tive, constrictive and mitogenic substances, and play a key role 
in acute coronary events and other thromboembolic diseases [2]. 
Mean platelet volume (MPV) is a marker of platelet function 
and activation. MPV and platelet distribution width (PDW) can 
be used as markers in the early diagnosis of diabetic compli-
cations in patients with type 2 diabetes mellitus (T2DM) [3]. 
Plateletcrit (PCT) levels are defined as an independent marker 
of vascular changes, particularly in the coronary arteries. The 
effect of platelet morphological parameters on metabolic control 
in patients with T1DM is still unclear. Very few studies have 
evaluated morphological changes in platelets, particularly in 
children and adolescents with T1DM. The purpose of this study 
was to assess platelet morphological parameters in children with 
T1DM and to determine the factors affecting those parameters.
Materials and Methods
Eighty patients diagnosed with T1DM, age between 3.9 - 17.6 
years and followed up by the Pediatric Endocrinology Clinic 
were included in the study. Patients with a history of drug use, a 
history of accompanying chronic disease, with findings of cur-
rent acute infection, or with severe hypoglycemia or diabetic 
ketoacidosis were excluded. A control group was established 
consisting of 80 subjects with no history of chronic disease pre-
senting to the pediatric clinic for routine check-up. This study 
was approved by Baskent University Institutional Review 
Board. Clinical Investigations Ethical Committee approval was 
obtained for the study and with the 1964 Helsinki Declaration 
and its later amendments or comparable ethical standards.
Data collection
All subjects’ anthropometric parameters (weight, weight stand-
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ard deviation score (SDs), height, height SDs, body mass index 
(BMI) and BMI SDs) and platelet count (PLT), MPV, PDW, 
PCT levels were recorded. Age at diagnosis, duration of dia-
betes, and hemoglobin A1c (HbA1c) levels of patients with 
T1DM were also obtained. Anthropometric data were convert-
ed to standard deviation scores using Turkish standard data [4]. 
BMI was calculated using the standard formula weight/height2 
(kg/m2). Type 1 DM patients were also stratified according to 
good (n = 14), moderate (n = 30) and poor metabolic control (n 
= 36) which were defined as: HbA1c < 7.5%, 7.5-9% and > 9% 
respectively. Target HbA1c levels of < 7.5%, based on ADA/
IDF/ISPAD recommendations [5].
Laboratory analyses
Blood samples were processed within 2 h after collection, 
according to the standard operating procedure of our institu-
tion. Platelets morphology parameters, e.g. PLT, MPV, PDW 
and PCT were extracted from routinely performed complete 
blood count results. The blood counts were performed with 
flow cytometry peroxidase methodology-based analyses (Sie-
mens Advia 2020i, Ireland). HbA1c was measured using the 
spectrophotometric methods. HbA1c measurements were 
performed with the Siemens Advia 1800 Chemistry System 
(Japan).
Statistical analysis
Statistical evaluation was performed by statistical package 
SPSS version 17(SPSS Inc, Chicago, IL). Data were expressed 
as mean ± standard deviation. The parameters with normal 
distribution were compared within two groups using Student’s 
t-test, whereas the parameters with non-normal distribution 
were compared within the two groups using the Mann-Whit-
ney U test. Pearson’s correlation analysis was used to assess 
the relationships between the parameters that showed normal 
distribution and Spearman’s rho correlation analysis was per-
formed to analyse the relationships between the parameters 
that did not show normal distribution. Spearman’s rho correla-
tion test was used for the comparisons of categorical variables 
and correlations among two variables. Kruskal-Wallis test 
which is a nonparametric test was used for the comparison of 
multiple groups. A P value < 0.05 was considered statistically 
significant.
Results
The mean age of enrolled subjects was 11.41 ± 3.79 years 
(range: 3.9 - 17.6 years) with mean duration of T1DM of 3.91 
± 2.76 years (range: 0.6 - 15 years). Age at diagnosis was 7.64 
± 3.49 years. The study and control groups did not differ in 
terms of sex and age. The basal characteristics of the study 
groups were shown in Table 1.
There was no significant difference in PCT, PLT, PDW 
and MPV values between patients and controls (P > 0.05) (Ta-
ble 2).
Influence of metabolic control on platelet morphology in-
dices
Patients were divided into three groups according to HbA1c 
levels (HbA1c < 7.5%, 7.5-9% and > 9%), PCT and PLT val-
ues were higher in patients with poor metabolic control com-
pared to the other cases (P = 0.002, P = 0.005). There was no 
statistically significant difference between the degree of meta-
bolic control and MPV and PDW levels (P > 0.05).
Correlation of platelet indices with various disease-related 
factors
There was no correlation between duration of diabetes and 
MPV, PDW, PCT and PLT. Positive correlation was found 
between HbA1c and PCT (r = 0.28, P = 0.01). There was no 
correlation between HbA1c and MPV, PDW and PLT (Table 
3).
Table 1.  Clinical Characteristics of the Study and Control 
Groups
Type 1 DM Control P values
Age 11.41 ± 3.79 10.61 ± 2.86 0.134
Gender ratio (boys/girls) 41/39 38/42 0.752
Weight SDs 0.01 ± 1.16 0.06 ± 1.47 0.738
Height SDs -0.13 ± 1.22 0.08 ± 1.46 0.297
BMI SDs 0.12 ± 1.03 0.17 ± 1.31 0.751
Diabetes duration 3.91 ± 2.76
HbA1c 9.11 ± 1.64
Type 1 DM: type 1 diabetes mellitus; SDs: standard deviation score; 
BMI: body mass index; HbA1c: hemoglobin A1c.
Table 2.  Platelet Parameters of the Study and Control Group
Type 1 DM (Mean ± SD) Control (Mean ± SD) P values
PLT (103/µL) 315.20 ± 62.81 315.98 ± 57.56 0.747
MPV (fL) 8.35 ± 1.06 8.13 ± 0.57 0.112
PDW (%) 45.65 ± 6.64 44.16 ± 4.79 0.083
PCT (%) 0.26 ± 0.06 0.25 ± 0.04 0.833
Type 1 DM: type 1 diabetes mellitus; PLT: platelet; MPV: mean platelet volume; PDW: platelet distribution width; PCT: plateletcrit.
Articles © The authors   |   Journal compilation © J Endocrinol Metab and Elmer Press Inc™   |   www.jofem.org146
Platelet Parameters in Type 1 Diabetes Mellitus J Endocrinol Metab. 2018;8(6):144-148
Discussion
Diabetes has been proved to be a prothrombotic condition. 
Platelets are cell fragments that play an active role in the devel-
opment of atherosclerosis and acute complications [6]. Large 
platelets are more active, contain more secretory granules, and 
produce more serotonin beta thromboglobulin and thrombox-
ane A2, which support platelet aggregation. This is regarded 
as a mechanism that accounts for platelet hyperactivity and 
thus their effects on thrombosis [7, 8]. MPV is a direct marker 
of platelet activity and function [9]. Studies have determined 
higher MPV in individuals with both T1DM and T2DM, and 
these changes have been linked to metabolic control [10, 11]. 
Sharpe et al [11] determined a significant increase in MPV 
values in patients with T1DM compared to healthy controls. 
Venkatesh et al [12] determined a significant increase in MPV 
values in subjects with childhood T1DM compared to a con-
trol group. Various different studies have thus suggested that 
platelets can be used as a marker for predicting an increase in 
the risk of the micro- and macrovascular complications of dia-
betes [13-15]. However, Ersoy et al [16] reported similar MPV 
values in children diagnosed with T1DM to those in a control 
group (8.74 ± 0.96 and 8.49 ± 0.66, respectively), although 
correlation was determined between intima-media thickness 
and MPV values. Similarly, in our study, we determined no 
statistically significant difference in MPV values between chil-
dren with T1DM and the control group. This may be explained 
in terms of the hypothesis that metabolic imbalance in diabetic 
cases does not yet lead to changes in MPV values in the early 
period due to the short duration of the disease in childhood.
Different results have been reported in studies assessing 
platelet counts in diabetic patients. Platelet activation and ag-
gregation resulting from an overreaction to endogenous ago-
nists in diabetic patients can lead to depletion of platelets in 
the circulation. Some studies support the idea that ineffec-
tive thrombopoiesis in diabetic subjects leads to a low plate-
let count [17, 18]. Hekimsoy et al [19] also observed a lower 
platelet count in diabetic cases. They suggested that this might 
also be related to differences in platelet production and turno-
ver in cases of T2DM. Pirgon et al [20] determined no sig-
nificant difference in platelet numbers between children with 
T1DM and controls (333.7 ± 71.3 × 109/L, and 339.6 ± 101.9 × 
109/L, respectively). Another study of T2DM patients reported 
a higher platelet count in the diabetic group than in the control 
group, although the difference was not statistically significant. 
A different study involving adult patients with T1DM deter-
mined a higher platelet count in diabetics than in the control 
group, and observed positive correlation with poor metabolic 
control [21]. Reactive thrombocytosis associated with increas-
ing blood glucose levels has been reported in diabetic patients 
with poor metabolic control. An increasing platelet count has 
been described as a possible response to stress, and to be capa-
ble of increasing the risk of vascular complications by damag-
ing the microcirculation. In the present study, we determined 
no difference in platelet counts between children with T1DM 
and the control group. However, we observed a higher platelet 
count in cases with poor metabolic control (HbA1c > 9%) than 
in the other groups (P = 0.005). Ta
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Vagdatli et al [22] in their study determined that PDW 
levels can be used as a specific marker of platelet activation. 
Malachowska et al [23] determined an increase in PDW val-
ues in cases of T1DM compared to a control group. This large 
study of adults with T2DM reported that duration of diabetes 
was positively correlated with PDW and MPV. That study also 
reported positive correlation between PDW and HbA1c [3]. 
We observed no statistically significant difference in PDW be-
tween our study groups. No correlation was also observed be-
tween HbA1c levels and PDW (r = -0.10, P = 0.376). Previous 
studies have shown correlation between duration of diabetes 
and increasing MPV values [24], although others do not sup-
port this [13]. No relation between duration of diabetes and 
MPV was observed in our study.
PCT is assumed to show the number of platelets in circu-
lation in one unit volume, and expresses platelet variation and 
heterogeneity [25]. There have been few studies of PCT values 
in diabetic cases, although Venkatesh et al [12] found no sig-
nificant difference in terms of PCT values between children 
diagnosed with T1DM and a control group. Another study of 
patients with T2DM determined higher PCT values than in a 
control group. That study also determined higher PCT values 
in the presence of chronic complications. This finding was at-
tributed to an increase in platelet mass, and thus in PCT, since 
platelets in diabetic patients are larger and more reactive [26]. 
In our study, however, we determined no difference in PCT 
between the T1DM patient group and the control group.
Hyperglycemia results in non-enzymatic glycosylation of 
proteins on the platelet surface, and therefore results in a de-
crease in membrane fluidity and an increase in platelet reactiv-
ity. A few studies have investigated relations between metabol-
ic control and platelet morphological parameters in children 
with T1DM. A retrospective study from 2015 involving 4,072 
patients reported a positive relationship between HbA1c levels 
and MPV [27]. Malachowska et al [23] observed no signifi-
cant relation between MPV and HbA1C. Zaccardi et al [28] 
observed a significant change in MPV-platelet count in cases 
with poor metabolic control (HbA1c > 9%) compared to other 
cases. Another large study of adults with T2DM reported sig-
nificant positive correlation between HbA1c levels and MPV 
[29]. Although Pirgon et al [20] observed higher MPV in cases 
with T1DM compared to a control group; they determined no 
significant correlation between MPV and HbA1c, BMI or age. 
Demirtunc et al [30] reported significantly higher MPV in pa-
tients with HbA1c values > 7% compared to those with HbA1c 
≤ 7%. In our study, positive correlation was found between 
HbA1c and PCT. The PCT values were higher in cases with 
poor metabolic control. This finding supports the idea that PCT 
values can be used as a marker in determining the risk of future 
complications, particularly in individuals with poor metabolic 
control. PCT may be an early marker of vascular damage in 
these cases.
There are a number of limitations to our study. In partic-
ular, metabolic control was determined only on the basis of 
HbA1c levels. However, greater glycemic variability is regard-
ed as an independent risk factor in the development of vascu-
lar complications of diabetes [31]. Use of continuous glucose 
measurement systems in these cases might therefore have in-
creased the power of our study.
Conclusions
Indices of platelet morphology such as MPV, PDW, PCT and 
PLT were similar in children with T1DM and in healthy con-
trols. This may be associated with young age and a short dura-
tion of diabetes. However, an increase in PCT values in poor 
glycemic control group and a significant positive correlation 
between PCT and HbA1c were observed, suggesting that PCT 
levels may be an early marker of vascular complication. Since 
PCT analysis is simple and inexpensive, it can be employed as 
a simple prognostic method for determining the risk of diabet-
ic complications. Further long-term prospective studies with 
larger patient series are now needed on this subject.
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